MSD Animal Health to Purchase Manufacturing Facility in Krems, Austria
August 07 2017 - 7:00AM
Business Wire
European Facility Will Boost Global Vaccine
Production Capacity
MSD Animal Health, known as Merck Animal Health in the United
States and Canada, today announced plans to purchase a new
manufacturing facility in Krems an der Donau, Austria with the
intention to expand its global vaccine manufacturing capacity. The
facility, currently owned by Shire plc., was built in 2002 and will
add to the company’s impressive global manufacturing
capabilities.
“This new manufacturing site is ideally located in central
Europe. It provides MSD Animal Health additional manufacturing
resources and advanced technology platforms to meet the growing
demand for our vaccine products that prevent disease and keep
animals healthy while positioning us for strong long-term growth,”
stated Joseph Morrissey, senior vice president, operations, MSD
Animal Health.
“We are excited to expand our footprint to Krems,” stated Dr.
Hans-Günther Dittrich, vice president, Europe, Russia, North
Africa, Middle East region. “Krems is the home to several distinct
universities, and a rich tradition as an economic center for
bio-pharmaceuticals. It is a great opportunity for us to tap into
the innovative science in the area.”
MSD Animal Health has a substantial global manufacturing
footprint and is a leader in animal health vaccines with a range of
global vaccines products for animal health diseases.
MSD Animal Health intends to immediately begin renovating the
facility and expects to be ready for production in the coming
years. Additional terms of the deal will not be disclosed.
About MSD Animal Health
For more than a century, MSD, a leading global biopharmaceutical
company, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases. MSD
Animal Health, known as Merck Animal Health in the United States
and Canada, is the global animal health business unit of MSD.
Through its commitment to the Science of Healthier Animals™, MSD
Animal Health offers veterinarians, farmers, pet owners and
governments one of the widest range of veterinary pharmaceuticals,
vaccines and health management solutions and services. MSD Animal
Health is dedicated to preserving and improving the health,
well-being and performance of animals. It invests extensively in
dynamic and comprehensive R&D resources and a modern, global
supply chain. MSD Animal Health is present in more than 50
countries, while its products are available in some 150 markets.
For more information, visit www.msd-animal-health.com or connect
with us on LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2016
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170807005047/en/
MerckMediaPam Eisele,
267-305-3558Pamela.eisele@merck.comorNoreen Verbrugge,
973-937-5450Noreen.verbrugge@merck.comorInvestor RelationsAmy Klug,
908-740-1898Amy.klug@merck.com
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024